A Phase 2 interventional study of Nanoparticle Paclitaxel in Vascular Disease, Peripheral, sponsored by Celgene Corporation. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 152nd largest by enrollment of the 158 interventional ones that give a count, is one of 13 that started in 2008, is one of 24 in phase 2, and was the 49th registered.
443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.
Browse Peripheral Vascular Diseases studies →18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:
Cook Research Incorporated · Sites in United States
Ages 18+
Corewell Health West · Sites in United States
Ages 45+
Northwestern University · Sites in United States
Ages 18+
MIMOSA Diagnostics Inc. · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 50–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 36 · Phase 3 25 · Phase 4 11
First in 1994; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 80 across 327 interventional studies indexed under Peripheral Vascular Diseases.
Median enrollment 82 across the 158 interventional studies, 200 across the 26 observational. Of the 147 that completed or were terminated, 57 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
Bristol-Myers Squibb has 1 study filed under Peripheral Vascular Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Vascular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT06319339University of NebraskaImpact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease | 2026-12 |
| NCT04922762Virginia Commonwealth UniversityExamining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2 | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following revascularization, participants did not receive any study drug treatment.
Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.
Drug: Nanoparticle Paclitaxel
Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization.
Drug: Nanoparticle Paclitaxel
Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m\^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.
Drug: Nanoparticle Paclitaxel
Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
Also known as: ABI-007, Abraxane®, Coroxane™
Target Vessel Revascularization at 9 Months
Target vessel revascularization (TVR) was defined as percutaneous revascularization or bypass of the target lesion or any segment of the artery containing the target lesion. The percentage of participants requiring revascularization of the target vessel was determined by stenosis of \> 50% confirmed by angiography.
Time frame: 9 months
Systolic Velocity Ratio (SVR) > 2.0
The percentage of participants with a systolic velocity ratio \> 2.0 assessed using lower extremity arterial duplex ultrasound.
Time frame: 9 months
Change From Baseline in Walking Impairment Questionnaire (WIQ) Score
The Walking Impairment Questionnaire (WIQ) is utilized to characterize a patient's walking ability. Scores range from 0 (no difficulty) to 100 (much difficulty).
Time frame: Baseline and Month 9
Decrease in Ankle Brachial Index (ABI) > 0.15
The percentage of participants with a decrease in the Ankle Brachial Index (ABI) \> 0.15. Ankle Brachial Index = Systolic Ankle Pressure / Systolic Brachial Pressure.
Time frame: Baseline and Month 9
Target Lesion Revascularization (TLR) at 9 Months
Target lesion revascularization (TLR) was defined as repeat percutaneous intervention or bypass surgery of the previously treated target lesion (or blockage). The percentage of participants requiring revascularization of the target lesion was determined by stenosis of \> 50% confirmed by angiography.
Time frame: 9 months
Number of Deaths
Number of patients who died due to any cause.
Time frame: Up to 11 months
Number of Participants With Myocardial Infarction (MI)
The number of patients experiencing Myocardial Infarction (MI) during the study. Myocardial Infarction was defined as new pathologic Q waves of at least 0.04 seconds, or an increase in serum creatine kinase to more than twice the normal code together with a pathologic increase in myocardial isoenzymes.
Time frame: Up to 11 months
Number of Participants With a Stroke
The number of patients experiencing a stroke during the study. Stroke was defined as any sudden development of neurological deficits lasting more than 24 hours, and if a brain imaging study is performed it shows an infarction or hemorrhage. A transient ischemic attack is a neurological deficit lasting less than 24 hours and, if an imaging study is performed, shows no evidence of infarction or hemorrhage.
Time frame: Up to 11 months
Minimum Lumen Diameter
Minimum lumen diameter (MLD) is defined as the smallest diameter in millimeters (mm) in the arterial segment of interest measured angiographically.
Time frame: 9 months
Late Loss
Late loss is defined as minimum lumen diameter (MLD) immediately post-procedure minus MLD at the time of follow-up, in mm.
Time frame: Day 1 (following revascularization) and 9 months
Percentage of Participants With Binary Restenosis
Binary restenosis was defined by a \>50% diameter stenosis at follow-up study, assessed by angiography.
Time frame: 9 months
Diameter Stenosis
Diameter stenosis is calculated as \[1 - (minimum lumen diameter (MLD) / reference vessel diameter)\] \* 100, where the reference vessel diameter is the vessel diameter measured in a healthy segment of the target vessel proximal as close as possible to the lesion.
Time frame: 9 months
| Milestone | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| Started | 0 | 3 | 1 | 2 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Study termination | 0 | 2 | 1 | 2 |
Target vessel revascularization (TVR) was defined as percutaneous revascularization or bypass of the target lesion or any segment of the artery containing the target lesion. The percentage of participants requiring revascularization of the target vessel was determined by stenosis of \> 50% confirmed by angiography.
No measurements were reported for this outcome.
The percentage of participants with a systolic velocity ratio \> 2.0 assessed using lower extremity arterial duplex ultrasound.
No measurements were reported for this outcome.
The Walking Impairment Questionnaire (WIQ) is utilized to characterize a patient's walking ability. Scores range from 0 (no difficulty) to 100 (much difficulty).
No measurements were reported for this outcome.
The percentage of participants with a decrease in the Ankle Brachial Index (ABI) \> 0.15. Ankle Brachial Index = Systolic Ankle Pressure / Systolic Brachial Pressure.
No measurements were reported for this outcome.
Target lesion revascularization (TLR) was defined as repeat percutaneous intervention or bypass surgery of the previously treated target lesion (or blockage). The percentage of participants requiring revascularization of the target lesion was determined by stenosis of \> 50% confirmed by angiography.
No measurements were reported for this outcome.
Number of patients who died due to any cause.
| participants | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| Number of Deaths | — | 1 | 0 | 0 |
The number of patients experiencing Myocardial Infarction (MI) during the study. Myocardial Infarction was defined as new pathologic Q waves of at least 0.04 seconds, or an increase in serum creatine kinase to more than twice the normal code together with a pathologic increase in myocardial isoenzymes.
| participants | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| Number of Participants With Myocardial Infarction (MI) | — | 0 | 0 | 0 |
The number of patients experiencing a stroke during the study. Stroke was defined as any sudden development of neurological deficits lasting more than 24 hours, and if a brain imaging study is performed it shows an infarction or hemorrhage. A transient ischemic attack is a neurological deficit lasting less than 24 hours and, if an imaging study is performed, shows no evidence of infarction or hemorrhage.
| participants | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| Number of Participants With a Stroke | — | 0 | 0 | 0 |
Minimum lumen diameter (MLD) is defined as the smallest diameter in millimeters (mm) in the arterial segment of interest measured angiographically.
No measurements were reported for this outcome.
Late loss is defined as minimum lumen diameter (MLD) immediately post-procedure minus MLD at the time of follow-up, in mm.
No measurements were reported for this outcome.
Binary restenosis was defined by a \>50% diameter stenosis at follow-up study, assessed by angiography.
No measurements were reported for this outcome.
Diameter stenosis is calculated as \[1 - (minimum lumen diameter (MLD) / reference vessel diameter)\] \* 100, where the reference vessel diameter is the vessel diameter measured in a healthy segment of the target vessel proximal as close as possible to the lesion.
No measurements were reported for this outcome.
Collected over Up to 11 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | — | — | — |
| Proximal to Lesion + IV | — | 1/3 (33.3%) | 1/3 (33.3%) |
| During Flow Arrest | — | 0/1 (0%) | 0/1 (0%) |
| During Flow Arrest + IV | — | 0/2 (0%) | 0/2 (0%) |
| Event | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | — | 1/3 | 0/1 | 0/2 |
| Event | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | — | 1/3 | 0/1 | 0/2 |
| Pain in extremityGastrointestinal disorders | — | 1/3 | 0/1 | 0/2 |
| DisorientationPsychiatric disorders | — | 1/3 | 0/1 | 0/2 |
| HaematomaVascular disorders | — | 1/3 | 0/1 | 0/2 |
| Age Continuous(years) | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV | Total |
|---|---|---|---|---|---|
| Mean | — | 69.7 ± 10.50 | 84.0 ± NA | 69.0 ± 12.73 | 71.8 ± 10.59 |
| Gender(participants) | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV | Total |
|---|---|---|---|---|---|
| Female | — | 0 | 0 | 1 | 1 |
| Male | — | 3 | 1 | 1 | 5 |
| Race/Ethnicity, Customized(participants) | Control | Proximal to Lesion + IV | During Flow Arrest | During Flow Arrest + IV | Total |
|---|---|---|---|---|---|
| Asian | — | 0 | 0 | 1 | 1 |
| White, Non-Hispanic and Non-Latino | — | 3 | 1 | 1 | 5 |
The record gives a start of Jan 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel
Peripheral Vascular Diseases →